-
公开(公告)号：KR1020100132878A
公开(公告)日：2010-12-20
申请号：KR1020090051688
申请日：2009-06-10
Applicant: (주)차바이오텍 , 가톨릭대학교 산학협력단
IPC: A61K9/06 , A61P41/00 , A61K31/728 , A61K31/336
CPC classification number: A61K31/728 , A61K9/06
Abstract: PURPOSE: An anti-adhesion agent containing hyaluronic acid epoxide derivative hydrogel and a method for manufacturing the same are provided to prevent adhesion between tissues without side effects. CONSTITUTION: An anti-adhesion agent contains hyaluronic acid epoxide derivative hydrogen. The particle size of the hydrogel is 100-300 um. The viscosity and crosslinking density of the hydrogel are 100,000 cP (0.02 Hz)-6,000,000 cP (0.02 Hz) and 0.2 mol%-100 mol%, respectively. The hydrogel is prepared by reacting hyaluronic acid and epoxide crosslinking agent in NaOH solution or crossliking 0.1-200 weight parts of crosslinking agent based on 100 weight parts of repeat unit of the hyaluronic acid.
Abstract translation: 目的：提供含有透明质酸环氧化物衍生物水凝胶的防粘连剂及其制造方法，以防止组织之间的粘连而无副作用。 构成：抗粘连剂含有透明质酸环氧化物衍生物氢。 水凝胶的粒径为100-300微米。 水凝胶的粘度和交联密度分别为100,000cP（0.02Hz）-6,000,000cP（0.02Hz）和0.2mol％-100mol％。 水凝胶是通过使透明质酸和环氧化物交联剂在NaOH溶液中反应制备的，或者以100重量份的透明质酸重复单元交联0.1-200重量份交联剂。
-
公开(公告)号：KR101180286B1
公开(公告)日：2012-09-14
申请号：KR1020090051688
申请日：2009-06-10
Applicant: (주)차바이오텍 , 가톨릭대학교 산학협력단
IPC: A61K9/06 , A61P41/00 , A61K31/728 , A61K31/336
Abstract: 본 발명은 히알루론산 에폭사이드 유도체 하이드로겔을 포함하는 유착방지제 및 이의 제조 방법에 관한 것이다. 보다 상세하게는, 본 발명은 수술 후 조직 간의 유착 방지 등의 용도로 사용되는 히알루론산 에폭사이드 유도체 하이드로겔을 포함하는 유착방지제 및 이의 제조 방법에 대한 것이다.
유착방지제-
3.发明公开
公开(公告)号：KR1020090012439A
公开(公告)日：2009-02-04
申请号：KR1020070076258
申请日：2007-07-30
Applicant: (주)차바이오텍 , 가톨릭대학교 산학협력단
IPC: A61K31/728 , A61P17/02
CPC classification number: A61K31/738 , A61K9/06 , A61K9/7007 , A61K2121/00
Abstract: A hyaluronic acid and a carboxy methyl cellulose composite derivative film is provided to have trachea reducing adhesion property, excellent biodegradation property and property absorbed by being completely disassembled after preventing adhesion phenomenon. An N-acylation urea pendant form and an auto-cross-linking form are mixed in hyaluronic acid and carboxy methyl cellulose composite derivative film. The N-acylation urea pendant form and an auto-cross-linking form are made by reacting crosslink activity agent and cross linkage activity supplement at hyaluronic acid and carboxy methyl cellulose complex film surface. The derivative film with the N-acylation urea pendant form is formed by using the crosslink activity agent 0.01 ~ 500 parts by weight and the cross linkage activity supplement 0.01 ~ 200 parts by weight based on compound of the carboxy methyl cellulose and hyaluronic acid 100 parts by weight. The derivative film with the auto-cross-linking form is formed by using the crosslink activity agent 0.01 ~ 500 parts by weight and the cross linkage activity supplement 40 ~ 1000 parts by weight.
Abstract translation: 提供透明质酸和羧甲基纤维素复合衍生物膜，以具有气管降低粘附性，优异的生物降解性能和性能在防止粘附现象后被完全分解吸收。 透明质酸和羧甲基纤维素复合衍生物膜混合N-酰化脲的侧链形式和自动交联形式。 通过在透明质酸和羧甲基纤维素复合膜表面上交联活性剂和交联活性补充剂反应制备N-酰化脲垂饰形式和自动交联形式。 通过使用0.01〜500重量份的交联活性剂和基于羧甲基纤维素和透明质酸化合物的交联活性补充0.01〜200重量份形成具有N-酰化脲侧链形式的衍生物膜100份 重量。 具有自交联形式的衍生物膜通过使用0.01〜500重量份的交联活性剂形成，交联活性为40〜1000重量份。
-
4.发明公开
公开(公告)号：KR1020120090485A
公开(公告)日：2012-08-17
申请号：KR1020110010942
申请日：2011-02-08
Applicant: (주)차바이오텍
IPC: A61K39/00 , C07K16/32 , C12N5/0783
CPC classification number: A61K39/0011 , A61K2039/505 , A61K2039/5158 , C07K16/32 , C07K2317/24 , C12N5/0646
Abstract: PURPOSE: A method for preparing lymphocytes including natural killer cells and a pharmaceutical composition containing the lymhocytes for targeting cancer cells are provided to treat cancer in which HER2/neu antigen is expressed. CONSTITUTION: A method for preparing lymphocytes including natural killer cells for targeting cancer cells which expresses HER2/neu antigens comprises: a step of adding a culture medium containing a natural killer cell surface protein antibody, serum, and interleukin-2 to a culture container coated with immunoglobulin G and culturing monocytes isolated from peripheral blood; and a step of treating anti-HER2/neu antibody to the culture medium and culturing.
Abstract translation: 目的：提供一种用于制备包括天然杀伤细胞的淋巴细胞的方法和含有用于靶向癌细胞的淋巴细胞的药物组合物，用于治疗HER2 / neu抗原表达的癌症。 构成：一种制备淋巴细胞的方法，包括用于靶向表达HER2 / neu抗原的癌细胞的天然杀伤细胞，包括：将含有天然杀伤细胞表面蛋白抗体，血清和白细胞介素-2的培养基加入到包被的培养容器中的步骤 用免疫球蛋白G和培养从外周血分离的单核细胞; 以及将抗HER2 / neu抗体处理至培养基并培养的步骤。
-
公开(公告)号：KR101072121B1
公开(公告)日：2011-10-10
申请号：KR1020080014937
申请日：2008-02-19
Applicant: 인하대학교 산학협력단 , (주)차바이오텍
Abstract: 본발명은최적화된배양방법에따른톨리포클라디움니베움()에서사이클로스포린 A를대량생산하기위한방법에관한것으로, 구체적으로포자형성, 균사체성장및 사이클로스포린생산단계별최적화된배양액을사용하고, 균사체성장배양시 포자접종량을조절함으로써사이클로스포린 A를대량생산하는방법에관한것이다. 본발명의방법을이용하여면역억제제및 항진균제로사용되는사이클로스포린 A를대량생산할수 있다.
-
Patent Agency Ranking
公开(公告)号：KR101444303B1
公开(公告)日：2014-11-04
申请号：KR1020120104477
申请日：2012-09-20
Applicant: 대한민국(농촌진흥청장) , (주)차바이오텍
Abstract: 본 발명은 누에 실샘 유래 가수분해물을 포함하는 화장료 조성물에 관한 것이다.
본 발명의 화장료 조성물은 누에 실샘 유래 가수분해물을 포함하는 것을 특징으로, 보다 상세하게는 누에로부터 실샘을 분리해 낸 다음, 그 분리된 실샘을 물로 용해한 후 원심분리하여 얻은 상등액에, 알칼리를 첨가한 후 가수분해한 다음 중화 및 탈염과정을 거쳐 얻은 가수분해물을 포함하는 것이 특징이다.
본 발명에 의해, 인체 무해하면서 항산화능, 피부세포증식능, 피부 친화력 등이 우수한 누에 실샘 유래 가수분해물을 포함하는 화장료 조성물이 제공된다.-
公开(公告)号：KR101075414B1
公开(公告)日：2011-10-24
申请号：KR1020090008608
申请日：2009-02-03
Applicant: (주)차바이오텍
Abstract: 본발명은동종또는이종의단백질또는폴리펩티드를발현하기위한희귀방선균인세베키아베니하나 ()에서의신규한형질전환시스템에관한것으로, 구체적으로접합 (conjugation) 을이용한형질전환방법및 상기방법으로형질전환된유용생리활성물질의생물전환능력이향상된형질전환균주에관한것이다.
-
公开(公告)号：KR1020100089396A
公开(公告)日：2010-08-12
申请号：KR1020090008618
申请日：2009-02-03
Applicant: (주)차바이오텍
Abstract: PURPOSE: A novel transformation system in Tolypocladiium niveum is provided to enhance cyclosporine A productivity and to industrially and medically use. CONSTITUTION: A method for preparing transformed Tolypocladium niveum comprises: a step of forming protoplast of Tolypocladium niveum; a step of preparing a recombinant vector in which foreign gene is introduced; a step of transforming by mixing PEG and the recombinant vector together with the protoplast; and a step of selecting Tolypocladium niveum using a selection marker. The transformed Tolypocladium niveum produces cyclosporine A of high concentrate.
Abstract translation: 目的：提供一种新的Tolypocladiium niveum的转化系统，以提高环孢菌素A的生产力和工业和医学应用。 构成：制备转化的土壤球菌的方法包括：形成铁皮假单胞菌原生质体的步骤; 制备引入外源基因的重组载体的步骤; 通过将PEG和重组载体与原生质体混合来转化的步骤; 以及使用选择标记选择Tolypocladium niveum的步骤。 转化的Tolypocladium niveum产生高浓度的环孢菌素A.
-
公开(公告)号：KR1020090090081A
公开(公告)日：2009-08-25
申请号：KR1020080015342
申请日：2008-02-20
Applicant: 인하대학교 산학협력단 , (주)차바이오텍
Abstract: A method for forming spore of antifungal polyene generating actinomycetes is provided to optimize the conversion efficiency to spore under the condition of sonication and produce the spore having high concentration. A method for forming a spore of antifungal polyene generating actinomycetes comprises: a step of culturing antifungal polyene generating actinomycetes; a step of pulverizing by sonication; and a step of collecting changed spore. The antifungal polyene generating actinomyces is Pseudonocardia autotrophica or Streptomyces sp.
Abstract translation: 提供了一种形成抗真菌多烯生成放线菌孢子的方法，以在超声处理条件下优化孢子的转化效率，产生浓度高的孢子。 形成抗真菌多烯生成放线菌孢子的方法包括：培养产生抗真菌多烯的放线菌的步骤; 通过超声处理粉碎的步骤; 并收集改变孢子的一个步骤。 抗真菌多烯生成放线菌是自发性假诺卡氏菌属或链霉菌属（Streptomyces sp。
-
公开(公告)号：KR1020090089651A
公开(公告)日：2009-08-24
申请号：KR1020080014937
申请日：2008-02-19
Applicant: 인하대학교 산학협력단 , (주)차바이오텍
Abstract: A method for producing cyclosporine is provided to produce cyclosporine A by regulating the amount of spore inoculation in culturing mycelia. A method for producing a cyclosporine A comprises: a step of culturing Tolypocladium niveum in sterile semisynthetic medium agar for 8-12 days to form spore; a step of filtering the spore to remove areal mycelia; a step of inoculating the spore in 2.8-3.2%(v/v) of sterile semisynthetic medium to germinate; and a step of culturing in SM medium (synthetic medium) for 13-17 days to produce the cyclosporine A.
Abstract translation: 提供一种生产环孢菌素的方法，通过调节培养菌丝体中的孢子接种量来生产环孢素A. 环孢菌素A的制造方法包括：将无菌半合成培养基琼脂培养8天，形成孢子的步骤; 过滤孢子以去除区域菌丝体的步骤; 在2.8-3.2％（v / v）无菌半合成培养基中接种孢子以发芽的步骤; 和在SM培养基（合成培养基）中培养13-17天以产生环孢菌素A的步骤。
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.023 seconds)
